Comparison of the risk of SGLT2is and NonSGLT2is in leading to amputation: A network meta-analysis.
Sign Up to like & getrecommendations! Published in 2020 at "Journal of diabetes and its complications"
DOI: 10.1016/j.jdiacomp.2020.107803
Abstract: OBJECTIVE Whether sodium-glucose cotransporter 2 inhibitors (SGLT2is) increase the risk of amputation or not remains controversial. We aimed to evaluate the relative risk of different SGLT2is and Non-SGLT2i antihyperglycemic drugs (NonSGLT2is) in leading to amputation… read more here.
Keywords: amputation; risk; sglt2is; network meta ... See more keywords
SGLT2 Inhibitors and the Risk of Venous Thromboembolism: A Population-based Cohort Study.
Sign Up to like & getrecommendations! Published in 2023 at "British journal of clinical pharmacology"
DOI: 10.1111/bcp.15787
Abstract: AIM The cardiovascular benefits of sodium glucose co-transporter 2 inhibitors (SGLT2Is) result from their complex impact on coronary and arterial vessels. However, their effect on veins and the risk of venous thromboembolism (VTE) remains unclear.… read more here.
Keywords: sglt2is; venous thromboembolism; vte; risk ... See more keywords
SGLT2is vs. GLP1RAs Reduce Cardiovascular and All-Cause Mortality
Sign Up to like & getrecommendations! Published in 2021 at "Frontiers in Cardiovascular Medicine"
DOI: 10.3389/fcvm.2021.791311
Abstract: Lin et al. recently did a network meta-analysis based on cardiovascular (CV) outcome trials (CVOTs) of sodium-glucose cotransporter 2 inhibitors (SGLT2is) and those of glucagon-like peptide-1 receptor agonists (GLP1RAs). Due to the absence of CVOTs… read more here.
Keywords: sglt2is glp1ras; cause mortality; sglt2is; meta analysis ... See more keywords